Evidence of EMT in canine prostatic cancers is available and comprises overexpression of vimentin [266], repression of E-cadherin expression [267], changes in β-catenin localization [268], loss of E-cadherin, and β-catenin translocation in prostatic metastases [269]. This evidence concerns the gene CDH1 and prostate carcinoma.